Adefovirdipivoxl en es it fr

Adefovirdipivoxl Brand names, Adefovirdipivoxl Analogs

Adefovirdipivoxl Brand Names Mixture

  • No information avaliable

Adefovirdipivoxl Chemical_Formula


Adefovirdipivoxl RX_link

Adefovirdipivoxl fda sheet

Adefovirdipivoxl FDA

Adefovirdipivoxl msds (material safety sheet)

Adefovirdipivoxl MSDS

Adefovirdipivoxl Synthesis Reference

No information avaliable

Adefovirdipivoxl Molecular Weight

501.471 g/mol

Adefovirdipivoxl Melting Point

No information avaliable

Adefovirdipivoxl H2O Solubility

19 mg/mL at pH 2.0 and 0.4 mg/mL at pH 7.2.

Adefovirdipivoxl State


Adefovirdipivoxl LogP


Adefovirdipivoxl Dosage Forms

Tablet (10 mg)

Adefovirdipivoxl Indication

For the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

Adefovirdipivoxl Pharmacology

Adefovir dipivoxil a diester prodrug of adefovir. Adefovir is an acyclic nucleotide analog with activity against human hepatitis B virus (HBV). The concentration of adefovir that inhibited 50% of viral DNA synthesis (IC50) in vitro ranged from 0.2 to 2.5 μM in HBV transfected human hepatoma cell lines. The combination of adefovir with lamivudine showed additive anti-HBV activity.

Adefovirdipivoxl Absorption

Approximate oral bioavailability is 59%.

Adefovirdipivoxl side effects and Toxicity

Renal tubular nephropathy characterized by histological alterations and/or increases in BUN and serum creatinine was the primary dose-limiting toxicity associated with administration of adefovir dipivoxil in animals. Nephrotoxicity was observed in animals at systemic exposures approximately 3–10 times higher than those in humans at the recommended therapeutic dose of 10 mg/day.

Adefovirdipivoxl Patient Information

Adefovirdipivoxl Organisms Affected

Hepatitis B virus